Novartis | NOVN - SCHULD





SCHULD Veränderung Datum
AbbVie USD 67.5B 67.5B 2025-12
Alcon AG USD 5.25B 4.74B 2026-03
Almirall EUR 342.86M 61.94M 2025-12
Amgen USD 54.6B 17M 2025-12
AstraZeneca USD 33.92B 4.3B 2026-03
Autolus Therapeutics Ltd USD 253.44M 8.84M 2025-03
Bayer EUR 36.45B 2.93B 2025-12
Biogen USD 6.56B 275.1M 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Eli Lilly USD 42.5B 3.6M 2025-12
Fresenius EUR 11.93B 919M 2025-12
Fresenius Medical Care EUR 11.03B 233.8M 2026-03
Genmab DKK 148M 5M 2025-06
Gilead Sciences USD 24.94B 5M 2025-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
GRIFOLS EUR 9.57B 746.56M 2025-12
Hikma Pharmaceutical USD 1.56B 252M 2025-06
J&J USD 47.93B 2.14B 2025-12
Lakefront Biotherapeutics EUR 6.44M 480K 2026-03
Lonza CHF 4.71B 915M 2024-12
Merck EUR 11.95B 152M 2025-12
Merck USD 49.34B 7.97B 2025-12
Novartis USD 47B 11.62B 2026-03
Novartis USD 32.02B 615M 2025-09
Novo Nordisk DKK 118.72B 61.75B 2025-03
Orion EUR 305.4M 15.8M 2025-12
Pfizer USD 63.73B 231M 2026-03
Philips EUR 7.81B 574M 2025-12
Recordati EUR 2.47B 37.48M 2025-12
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Roche Holding CHF 33.03B 1.41B 2025-06
Sanofi EUR 20.33B 1.43B 2025-12
UCB EUR 3.03B 12M 2024-12